How will Healthcare Contract Development Look Like After the Covid-19 Pandemic?

9 mins read

Driven by the healthcare contract development, a third-party organization plays a vital role in keeping up operations at the pace for the destined healthcare institution in the time of crisis.

Information technology has a far-reaching impact on the healthcare sector since the IT utilities are getting consumed nearly in every field. IT deployments make everything easy and aligns the resources in the best possible array to extract the desired output.

Contracts in the healthcare sector have attained new reforms as global health issues have surged up. Therefore, based on the value reforms, many experts from healthcare attempt to explain the various type of value-based contracting with health systems.

A recent survey for selecting healthcare contracts stated that value-based contracting is much ideal and is a highly promised one.

Value-based contracting occurs between the two parties wherein both the parties participate in the risk-sharing agreement. The parties can be two healthcare systems, such as vendors and biopharmaceutical manufacturers. The purpose of this type of contract is to cover the product’s utility based on its effectiveness and frequency of utility. These arrangements are made to enhance the cost of drugs so that the provider can produce optimal results in terms of patient care.

Besides, this proves to be an innovative and widely adopted approach since it delivers precise outcomes. Therefore, high adoption makes it a widely popular option in the healthcare industry.

Stability is the foremost factor in the line of contract development as the healthcare industry continues to grow rapidly as the yearly growth of the pharmaceuticals market is expected to reach around 10-12% in the next 7-8 years, as per IQVIA. The drug sales market is anticipated to witness an annual growth of 12% in the next two to three years. Additionally, the contract development and manufacturing organization represent a large part of the development process, and their major role is to ensure the availability of biological products in the end-user markets.

An efficient healthcare system enables healthcare organizations to offer optimal care to patients, keep operating costs under control, and ensure the pursuit of strict compliance with medical standards. Besides, the contract management systems reflect upon the healthcare-related complexities to simplify the approach in the development stage, usually done by streamlining the process for contract reviewing and approval. Hence, the desired time and ideal time for complete agreement and negotiation stand important during the progress of a healthcare contract development.

Why healthcare companies suffer in the wake of Covid-19?

The Covid-19 pandemic has put the world economy on a roller coaster ride. Nations are now at the edge where healthcare systems are getting restrained by the burden of failure led by the ongoing disruption. The future of contract development might become bleak if healthcare systems fail to respond resiliently.

Vendors and outsourced parties have huge responsibilities based on the priorities and available pool of resources. The nature of the agreement varies in terms of demand. It is evident because healthcare businesses are going through turmoil, and herein vendors will have to identify the gap to create sustainable opportunities.

Healthcare companies will continue to suffer due to the emergence of the pandemic, increase in patient pools, and need for more resources. As worldwide companies are progressing towards developing the Covid-19 vaccine, they are prioritizing R&D for diagnosis, treatment, vaccine, and other existing treatment for coronavirus. Even though the pharmaceutical companies possess thorough scientific knowledge through decades of experience, the combat against the novel coronavirus is relentless.

A few companies will work under the partnership, joint venture, or contract-based model for extensive research and development. A few are listed below (under the scope of this post).

  • Alexion is a global biopharmaceutical company that stresses on patients and families with rare and chronic disorders. It has initiated a Phase III clinical trial for patients with Covid-19 pneumonia or respiratory distress syndrome. NHS centers are also taking the help of Alexion medicine to conduct their clinical trials.
  • Boehringer Ingelheim is looking forward to expanding a team of more than 100 scientists and professionals to conduct comprehensive research on SARS CoV-2.
  • MSD is a dedicated and competent company focusing on life improvement, and protection of employee and their family safety also complying with the supply chain of medicine and vaccine for the population. 

There are many more in the list reflecting contingency studies for clinical trials and have partnered with companies ranging from small startups to big brands. The overall significance of the entire arrangement is to exhibit concreteness and support for healthcare institutions without ending in the crisis.

Healthcare contract development scenario after the pandemic

Based on gathered data and the prolonged prevalence of the pandemic, several healthcare systems are going through an economic grind. There can be several assumptions on how the healthcare contract development process can look like after the pandemic.

According to Capgemini, the survival of healthcare systems depends on emphasizing:

> Protection of business interests and revenue,

> Continue to deliver business with or less disruption,

> People services and welfare practices.

While most organizations are adopting cost-cutting models and layoffs, several are looking to delay certain payments. Also, a few companies are keen upon force majeure clauses to suspend or terminate contracts. Capgemini’s advice to remain consistent with the business continuance planning (BCP) from the contract management perspective offers optimism as currently, everyone is sailing in the same boat.

The best practices for effective contract management can prove fruitful in terms of cost and performance. For example, auditing the contracts at certain intervals can result in identifying errors, and placing appropriate steps can eventually save millions for a healthcare institution. Rather than focusing on spending issues, vendors can work to provide solutions that offer good commercial value along with enhancing patient care and treatment. In another instance, risk management and mitigation practices can help healthcare organizations to maintain a high resilience and improved compliance supported by performance analytics.

Overall, the healthcare contract development market will surely offer lucrative opportunities in the coming future.

About GVR

Grand View Research is an India & U.S. based market research and consulting firm headquartered in San Francisco, which offers syndicated research reports, customized research reports, and consulting services. Our products and services have proved to be of great help to some of the most renowned academic institutions and Fortune 500 companies in the world. We help clients make calculated, informed business decisions through competitive analysis spanning 46 industries, including chemicals, materials, energy, healthcare, food and beverage, and technology, across 25 major countries globally.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Ingenza meets a key milestone in the deployment of novel cost-effective COVID-19 vaccine technology
Previous Story

Ingenza meets a key milestone in the deployment of novel cost-effective COVID-19 vaccine technology

The first mobile processing machine for pilot scale applications - VENTILUS(R) Pilot by Romaco Innojet
Next Story

The first mobile processing machine for pilot scale applications - VENTILUS® Pilot by Romaco Innojet